Pharmacia Somavert Manufacturing Changes Planned For U.S. Approval
Pharmacia expects FDA approval of the acromegaly drug Somavert (pegvisomant) in the "next several months" pending clearance of a revised manufacturing process
You may also be interested in...
Labeling for Pharmacia's acromegaly treatment Somavert recommends monthly liver function monitoring for the first six months of treatment
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011